NCT06076824 (GLUCO-TAVR) is a Phase 4 clinical trial of Methylprednisolone in Heart Block, sponsored by Hospital General Universitario de Alicante.

Who is sponsoring NCT06076824?

NCT06076824 is sponsored by Hospital General Universitario de Alicante.

What drugs are being tested in NCT06076824?

Interventions in NCT06076824: Methylprednisolone, Placebo.

What condition does NCT06076824 study?

NCT06076824 studies Heart Block, Aortic Stenosis, Bundle-Branch Block.

Is NCT06076824 still recruiting?

NCT06076824 is currently status unknown. Last updated 11 October 2023.

Last reviewed 2023-10-11 · How we verify

NCT06076824: GLUCO-TAVR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Glucocorticoid Treatment in Transaortic Valve Replacement to Reduce the Incidence of Conduction Disturbances (GLUCO-TAVR).

Status unknown Phase 4 Last updated 11 October 2023

What this trial tests

Phase 4 trial testing Methylprednisolone in Heart Block in 100 participants. Status unknown.

Timeline

12 August 2023

Primary endpoint
1 September 2024

1 September 2024

Quick facts

Lead sponsor	Hospital General Universitario de Alicante
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	100
Start date	12 August 2023
Primary completion	1 September 2024
Estimated completion	1 September 2024
Sites	1 location across Spain

Drugs / interventions tested

Methylprednisolone (methylprednisolone) — full drug profile →
Placebo

Conditions studied

Heart Block — all drugs for Heart Block →
Aortic Stenosis — all drugs for Aortic Stenosis →
Bundle-Branch Block — all drugs for Bundle-Branch Block →

Sponsor

Hospital General Universitario de Alicante

Who can join

Eligibility, any sex, with Heart Block or Aortic Stenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this phase IV, randomized, controlled and open-label study is to assess the efficacy of peri-procedure glucocorticoid treatment in the prevention of conduction abnormalities and the need for pacemaker implantation in patients undergoing transaortic valve replacement compared to placebo. Participants randomized to the intervention group will receive a single dose of intravenous Methylprednisolone 7 mg/kg/day on the day of the procedure (1 hour before), followed by 15 mg/12 hours of daily Prednisone for 5 days. The primary endpoint is a composite of permanent pacemaker implantation and the occurrence of new conduction abnormalities (any-degree AV block, bundle branch block, or non-specific intraventricular conduction disorder) at discharge, at 30 days and 1 year.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Management of conduction disturbances after TAVI: the last step towards early discharge.
Muntané-Carol G, Romaguera R, Gómez-Hospital JA, Nuche J, et al · · 2025 · PMID 40607130 · DOI 10.26599/1671-5411.2025.05.004

Verify or expand the search:

Other trials of Methylprednisolone

Trials testing the same drug.

NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
NCT07455396 — Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): Trial of Dexamethasone Versus Methylprednisolone for Ped · Phase 2 · not yet recruiting
NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
NCT07357935 — Early Inflammatory-Immune Stratification and Precision Glucocorticoid Intervention in Acute Respiratory Failure Induced · Phase 1, PHASE2 · not yet recruiting
NCT07265258 — A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease · Phase 4 · not yet recruiting

Other recruiting trials for Heart Block

Currently open trials in the same condition.

NCT05015660 — Conduction System Pacing With Left Bundle Branch Pacing as Compared to Standard Right Ventricular Pacing · NA · recruiting

Other Hospital General Universitario de Alicante trials

Trials by the same sponsor.

NCT06967597 — Conservative Versus Proactive Management of Acute Cholecystitis After EUS-guided Transmural Gallbladder Drainage: FUGITI · NA · recruiting
NCT06899269 — SPAROBOPAN Project (Spanish Registry of Robotic Pancreatic Surgery) · not yet recruiting
NCT05689268 — EUS-PPG vs HVPG in Portal Hypertension · NA · completed
NCT05888753 — Textbook Outcome in Adrenal Neoplasms · completed
NCT05675904 — Textbook Outcome in Colon Carcinoma · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06076824 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital General Universitario de Alicante
Last refreshed: 11 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06076824.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing